Provided by Tiger Fintech (Singapore) Pte. Ltd.

Qudian Inc.

2.28
-0.3400-12.98%
Post-market: 2.280.00000.00%16:48 EDT
Volume:1.30M
Turnover:3.13M
Market Cap:431.84M
PE:85.02
High:2.58
Open:2.54
Low:2.23
Close:2.62
Loading ...

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25)

GlobeNewswire
·
30 Mar

Press Release: Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights

Dow Jones
·
28 Mar

Press Release: InnoCare Releases 2024 Results and Business Highlights

Dow Jones
·
27 Mar

New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings

Business Wire
·
26 Mar

Qudian Inc. Reports Strong 2024 Revenue Growth

TIPRANKS
·
25 Mar

The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics

Zacks
·
21 Mar

Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More

Zacks
·
21 Mar

EVgo And 2 Additional Promising Penny Stocks

Simply Wall St.
·
20 Mar

Qudian Inc. Reports 2024 Financial Results Amidst Competitive Challenges

TIPRANKS
·
20 Mar

Qudian: Q4 Earnings Snapshot

Associated Press Finance
·
20 Mar

Qudian Q4 EPS $0.05 Up From $(0.08) YoY, Sales $7.20M Down From $8.98M YoY

Benzinga
·
20 Mar

Qudian Inc: Qtrly Non-Gaap Net Income per Diluted Ads Was RMB0.37(US$0.05)

THOMSON REUTERS
·
20 Mar

Qudian Q4 Income From Operations RMB -111.278 Million

THOMSON REUTERS
·
20 Mar

Qudian Inc. Reports Fourth Quarter and Full Year 2024 Unaudited Financial Results

THOMSON REUTERS
·
20 Mar

INCY Stock Down on Disappointing Skin Disease Study Data

Zacks
·
19 Mar

ZJK Industrial Showcases Advanced Quick Disconnect Components at NVIDIA’s GTC25 Conference

GlobeNewswire
·
17 Mar

Geneva-based SGS Certifies Samsung Electronics' QD TV Sheet as Cadmium-Free

MT Newswires Live
·
12 Mar

Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

GlobeNewswire
·
10 Mar

Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress

PR Newswire
·
28 Feb

Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

GlobeNewswire
·
27 Feb